EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic medications. The aim of the EDGE study (Effectiv...

Full description

Bibliographic Details
Main Author:	Gagik Radikovich Galstyan
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2013-06-01
Series:	Сахарный диабет
Subjects:	diabetes mellitus hypoglycemic agents efficacy vildagliptine
Online Access:	https://www.dia-endojournals.ru/jour/article/view/3761

Similar Items

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-10-01)

Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke
by: Dong‐Yi Chen, et al.
Published: (2020-01-01)

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
by: Chin-Hsiao Tseng, et al.
Published: (2021-04-01)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Consensus statement by a panel of experts of the Russian Association of Endocrinologists (RAE) on initiation and intensificationof hypoglycemic therapy for type 2 diabetes mellitus
by: Ivan Ivanovich Dedov, et al.
Published: (2011-03-01)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
by: Chantal Mathieu, et al.
Published: (2008-12-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
by: Min Kyong Moon, et al.
Published: (2017-10-01)

Reprotoxic activities of vildagliptin administration in male Wistar rats
by: Akinsomisoye Olumide Stephen, et al.
Published: (2021-11-01)

Ethnomedicinal survey of traditional antidiabetic plants in Baturraden and Sumbang
by: Wahyu Utaminingrum, et al.
Published: (2020-08-01)

Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)

Comparison of efficacy of add-on therapy of vildagliptin versus pioglitazone among Type 2 Diabetes Mellitus patients inadequately controlled on dual therapy of metformin plus sulfonylurea
by: Kirandeep Kaur
Published: (2014-02-01)

Effect of vildagliptin on atherosclerosis progression in high cholesterol –fed male rabbits
by: Sahar A Majeed
Published: (2014-12-01)

Synergistic Benefits: Exploring the Anti-Virulence Effects of Metformin/Vildagliptin Antidiabetic Combination against <i>Pseudomonas aeruginosa</i> via Controlling Quorum Sensing Systems
by: Maan T. Khayat, et al.
Published: (2023-05-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
by: Sol Batule, et al.
Published: (2022-05-01)

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-09-01)

Determination of the vildagliptin intermediate enantiomer by chiralce-columns
by: Weina LI, et al.
Published: (2017-06-01)

Silver Nanoparticle Conjugation-Enhanced Antibacterial Efficacy of Clinically Approved Drugs Cephradine and Vildagliptin
by: Abdulkader Masri, et al.
Published: (2018-11-01)

Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Xiaoling Cai, et al.
Published: (2021-05-01)

Pharmacogenetics of hypoglycemic agents
by: Irina Vladimirovna Kononenko, et al.
Published: (2015-12-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
by: Takatoshi Anno, et al.
Published: (2019-01-01)

Prevalence and predictors of clinical inertia in patients with type 2 diabetes who were treated with a single oral antidiabetic drug
by: Ryo Suzuki, et al.
Published: (2023-01-01)

Antioxidant-antidiabetic agents and human health /
by: Oguntibeju, Oluwafemi, author
Published: (2014)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Cost Utility Analysis Vildagliptin dan Glimepiride dalam Mencegah Komplikasi Mikrovaskuler menggunakan Model Markov
by: Tri Julia Purnamasari, et al.
Published: (2023-12-01)

Insulin Fact Sheet in Type 1 and 2 Diabetes Mellitus and Trends of Antidiabetic Medication Use in Insulin Users with Type 2 Diabetes Mellitus: 2002 to 2019
by: Jiyun Park, et al.
Published: (2023-03-01)

Antidiabetic Effect of Artemisia deserti Ethanolic Extract in Normal and Streptozotocin-induced Diabetic Rats
by: Akram Eidi
Published: (2014-05-01)

A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn®) and Galvusmet® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions
by: Shiekmydeen J., et al.
Published: (2023-10-01)